Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Dihexa for Sale > 99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - large image1
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image1
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image2
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image3
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image4
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image5
99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg buy - image6

99% purity Dihexa Prebiotic dipeptide white powder 100mg 1000mg

169 Inquiries

Unit Price:

$100-130/G FOB

Get Latest Price
CAS No.:

1401708-83-5

Grade:

Pharmaceutical Grade

Content:

99%

Port:

qingdao

Brand:

SINOV

Packaging:

1vial

Price valid (until):

2026-10-01

Company Type:
Trader
Location:
Hongkong, China
Qualification:
Main Products:

Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  



    1. Description


    Dihexa is a synthetic peptide compound originally developed by a research team at a U.S. university by modifying a naturally occurring substance in the human body (angiotensin IV), with the goal of creating a “memory-enhancing” compound. What makes it unique is its mechanism of action: rather than directly stimulating a specific receptor in the brain, it “leverages” a protein in the body associated with cell growth and survival, amplifying its signals to promote the formation of new connections between brain cells. To put it simply, the brain’s memory and thinking rely on a dense network of connections between neurons, and Dihexa’s core function is to help the brain “build bridges”— —encouraging neurons to form more new connections. The more connections there are, the stronger the “hardware foundation” for learning, memory, and cognition becomes. It has several notable characteristics: First, it is extremely potent—it works at extremely low concentrations in the lab, and its efficacy has even been compared to that of the brain’s own key neurotrophic factor (BDNF).

    Second, it can cross the blood-brain barrier and is taken orally, making it very convenient for practical use. Currently, all findings regarding its effects come from animal and in vitro studies. For example, in mouse models of aging or brain injury, it has been shown to significantly improve spatial memory and learning ability. As a result, it is primarily used in scientific research exploring Alzheimer’s disease, cognitive impairment, and recovery from brain injury. It has not yet entered human clinical trials nor been approved for market release. In short, Dihexa is a research-grade peptide marketed for “enhancing memory and promoting neural connections in the brain.”

    2. Application

    (1) Promotes cognition and memory consolidation: Dihexa exhibits significant cognitive-enhancing activity, reversing learning deficits, improving spatial learning ability, and promoting memory consolidation and retrieval.

    (2) Induces synaptogenesis and dendritic spine formation: Dihexa induces dendritic spine formation and synaptogenesis in hippocampal neurons, acting similarly to HGF itself. These effects can be blocked by HGF antagonists and sh-RNA targeting c-Met.

    (3) Neurotrophic Activity: In neurotrophic activity assays, Dihexa exhibits potency seven orders of magnitude higher than brain-derived neurotrophic factor (BDNF). It activates the c-Met receptor, stimulates neurogenesis, and protects neurons from injury.

    (4) Enhanced HGF/c-Met Signaling: In the presence of subthreshold HGF concentrations, Dihexa induces c-Met phosphorylation and increases HGF-dependent cell scattering, significantly amplifying HGF's ability to activate c-Met.

    (5) Oral Activity with Long Circulating Half-Life: Dihexa exhibits oral bioavailability, blood-brain barrier permeability, and metabolic stability, enabling it to maintain a prolonged circulating half-life in vivo.

    3. Main Efficacy

    (1) Enhancing Cognitive Function and Memory Consolidation: Dihexa exhibits significant cognitive-enhancing activity, reversing learning deficits, improving spatial learning abilities, and promoting memory consolidation and retrieval.

    (2) Inducing Synaptic Formation and Dendritic Spine Development: Dihexa induces dendritic spine formation and synaptic generation in hippocampal neurons.

    (3) Neurotrophic Activity: In neurotrophic activity assays, Dihexa exhibits potency seven orders of magnitude higher than brain-derived neurotrophic factor (BDNF). It promotes neurogenesis by activating the c-Met receptor and protects neurons from injury.

    (4) Oral Bioavailability and Long Circulating Half-Life: Dihexa combines oral bioavailability, blood-brain barrier permeability, and metabolic stability, enabling it to maintain a prolonged circulating half-life in vivo.

    Shop Professional Factory Supply High Qulity Bengenin-Detailed Image 2

    Shop Cosmetic Raw Materials Hyaluronic Acid Powder-Detailed Image 2

    Items Specifications
    Origin China
    Purity

    5%-99%

    Appearance powder
    Color white
    Package

    Drum, Plastic Container, Vacuum Packed

    Shelf life

    2 years

    Storage

    Cool Dry Place

    ECHEMI Editorial Reference

    Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.

    Basic Info
    Product Name:

    Dihexa

    Other Name:

    L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide

    CAS No.:

    1401708-83-5

    Molecular Formula:

    C27H44N4O5

    InChIKeys:

    InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N

    Molecular Weight:

    504.7

    Exact Mass:

    504.66

    Categories:

    Polypeptide

    Characteristics
    Density:

    1.111±0.06 g/cm3(Predicted)

    Boiling Point:

    866.2±65.0 °C(Predicted)

    Research
    Class:

    Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator

    Status:

    Research compound — Not FDA approved

    Mechanism:

    A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.

    EC50 (HGF Binding KD):

    65 pM

    Activity note:

    Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).

    Source:

    Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.

    Clinical Development:

    NCT04488419

    References
    PubChem:

    PubChem

    UNII:

    9WYX65A5C2

    Disclaimer:

    Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332

    Location:

    Unit D01,3/F., Wong King Industrial Building,No.2 Tai Yau Street, Kowloon

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7

    Total Annual Revenue:

    $50 million-$100 million

    Total Employees:

    51-100

    Year of Establishment:

    2012

    We have more than 10 years experience in the pharmacy filed. Mainly manufactures pharmaceutical APIs,Pharmaceutical intermediate and Cosmetic raw material. Owing to the good quality and competitive price, we have a very good reputation in China's pharmaceutical circles.

    In the principle of "Quality Oriented", Jianfeng passed the certification of ISO9001:2008 Quality Management System.

    Our products are based on bulk, high volume, wholesale price, third party testing, certificate reporting, and bring high quality ingredients to many domestic and overseas enterprises.

    "Honesty, practicality, innovation, development" are our values. Jianfeng would like to cooperate with you with high quality products and competitive price.

  • Inquiry History
    169 Inquiries
    Country Product Purchase Quantity Date Posted
    Canada

    Dihexa lyophilized 1401708-83-5

    Aug 23, 2026
    Canada

    Dihexa 1401708-83-5

    1 G Mar 8, 2026
    Bulgaria

    Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5

    10 G May 27, 2025
    United States

    Dihexa

    500 G Aug 19, 2026
    United States

    Dihexa

    25 G Jan 26, 2025
    Russia

    DIHEXA

    50.00 G Aug 14, 2024
    Hungary

    Dihexa

    1 G Sep 7, 2026
    Spain

    Dihexa

    50 MG Aug 28, 2026
    Australia

    Dihexa

    20 MG Aug 7, 2026
    Belgium

    Dihexa

    10 G Jul 24, 2026
    United States

    dihexa

    1 G Jul 16, 2026
    United States

    Dihexa/Acetic Acid 3ml 0.6%

    10 PCS Jun 30, 2026
    Philippines

    dihexa

    10 MG Jun 23, 2026
    Philippines

    Dihexa 10mg liquid

    10 MT Jun 19, 2026
    Philippines

    Dihexa

    50 PCS Jun 4, 2026
    China

    Dihexa

    1 G May 28, 2026
    Australia

    dihexa

    30 MG May 26, 2026
    Germany

    Dihexa

    5 G May 4, 2026
    Netherlands

    Dihexa

    2 G May 1, 2026
    India

    Dihexa

    1 MT Apr 24, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.